Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$43.71 +2.0%	$37.63	$21.72 ▼ $45.48	$8.13B	1.15	2.50 million shs	2.46 million shs
BPMC Blueprint Medicines	$128.27 +0.1%	$111.90	$73.04 ▼ $128.52	$8.28B	0.89	1.32 million shs	1.35 million shs
EVTCY Evotec	$4.34 +2.8%	$4.13	$14.22 ▼ $26.57	$7.58B	0.98	2,407 shs	145,733 shs
GBT Global Blood Therapeutics	$68.49	$68.47	$21.65 ▼ $73.02	$4.62B	0.45	2.07 million shs	74 shs
MRTX Mirati Therapeutics	$58.70	$58.82	$27.30 ▼ $64.41	$4.12B	0.77	2.76 million shs	N/A

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	+0.12%	-3.49%	+20.78%	+25.71%	+71.94%
BPMC Blueprint Medicines	-0.11%	-0.04%	+0.32%	+47.17%	+16.17%
EVTCY Evotec	+0.48%	+3.43%	+6.30%	+30.65%	-13.17%
GBT Global Blood Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
MRTX Mirati Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BBIO BridgeBio Pharma	4.706 of 5 stars	4.5	2.0	0.0	3.9	2.4	3.3	0.6
BPMC Blueprint Medicines	1.7239 of 5 stars	2.1	4.0	0.0	0.0	2.7	0.8	0.6
EVTCY Evotec	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GBT Global Blood Therapeutics	0.2932 of 5 stars	0.0	0.0	0.0	4.0	0.0	0.0	0.6
MRTX Mirati Therapeutics	0.5461 of 5 stars	0.0	0.0	0.0	4.7	0.6	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBIO BridgeBio Pharma	2.93	Moderate Buy	$58.85	34.64% Upside
BPMC Blueprint Medicines	2.27	Hold	$128.06	-0.16% Downside
EVTCY Evotec	0.00	N/A	N/A	N/A
GBT Global Blood Therapeutics	0.00	N/A	N/A	N/A
MRTX Mirati Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest BPMC, BBIO, GBT, EVTCY, and MRTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	BBIO BridgeBio Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$67.00 ➝ $76.00
6/25/2025	BBIO BridgeBio Pharma	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$50.00 ➝ $54.00
6/17/2025	BBIO BridgeBio Pharma	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$49.00
6/17/2025	BPMC Blueprint Medicines	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$143.00 ➝ $129.00
6/9/2025	BBIO BridgeBio Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$53.00 ➝ $56.00
6/5/2025	BPMC Blueprint Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$102.00 ➝ $129.00
6/5/2025	BPMC Blueprint Medicines	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$88.00 ➝ $129.00
6/4/2025	BPMC Blueprint Medicines	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold	$83.00 ➝ $129.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$132.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold

(Data available from 7/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBIO BridgeBio Pharma	$221.90M	37.40	N/A	N/A	($7.71) per share	-5.67
BPMC Blueprint Medicines	$508.82M	16.28	N/A	N/A	$4.70 per share	27.29
EVTCY Evotec	$572.16M	2.50	$0.04 per share	105.53	$2.52 per share	1.72
GBT Global Blood Therapeutics	$194.75M	23.73	N/A	N/A	$3.05 per share	22.46
MRTX Mirati Therapeutics	$12.44M	331.01	N/A	N/A	$17.31 per share	3.39

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBIO BridgeBio Pharma	-$535.76M	-$3.53	N/A	N/A	N/A	-524.25%	N/A	-94.43%	7/30/2025 (Estimated)
BPMC Blueprint Medicines	-$67.09M	-$2.47	N/A	197.34	N/A	-27.70%	-64.60%	-17.22%	7/30/2025 (Estimated)
EVTCY Evotec	$7.14M	$0.41	10.59	∞	N/A	20.85%	16.02%	7.81%	N/A
GBT Global Blood Therapeutics	-$303.09M	-$5.01	N/A	N/A	N/A	-137.30%	-170.37%	-39.24%	N/A
MRTX Mirati Therapeutics	-$740.87M	-$12.22	N/A	N/A	N/A	-1,900.65%	-82.15%	-67.82%	N/A

Latest BPMC, BBIO, GBT, EVTCY, and MRTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/1/2025	Q1 2025	BPMC Blueprint Medicines	-$0.42	-$0.74	-$0.32	$0.01	$158.31 million	$149.41 million
4/29/2025	Q1 2025	BBIO BridgeBio Pharma	-$1.00	-$0.88	+$0.12	-$0.88	$57.14 million	$36.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
BPMC Blueprint Medicines	N/A	N/A	N/A	N/A	N/A
EVTCY Evotec	N/A	N/A	N/A	N/A	N/A
GBT Global Blood Therapeutics	N/A	N/A	N/A	N/A	N/A
MRTX Mirati Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBIO BridgeBio Pharma	N/A	4.57	4.54
BPMC Blueprint Medicines	1.01	2.80	2.75
EVTCY Evotec	0.53	2.57	2.50
GBT Global Blood Therapeutics	4.92	6.88	6.17
MRTX Mirati Therapeutics	N/A	7.54	7.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBIO BridgeBio Pharma	99.85%
BPMC Blueprint Medicines	N/A
EVTCY Evotec	N/A
GBT Global Blood Therapeutics	N/A
MRTX Mirati Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
BBIO BridgeBio Pharma	18.20%
BPMC Blueprint Medicines	4.21%
EVTCY Evotec	N/A
GBT Global Blood Therapeutics	4.90%
MRTX Mirati Therapeutics	3.26%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBIO BridgeBio Pharma	400	189.88 million	155.32 million	Optionable
BPMC Blueprint Medicines	640	64.58 million	61.86 million	Optionable
EVTCY Evotec	4,200	330.22 million	N/A	Not Optionable
GBT Global Blood Therapeutics	457	67.48 million	64.17 million	Optionable
MRTX Mirati Therapeutics	587	70.15 million	67.86 million	Optionable

BPMC, BBIO, GBT, EVTCY, and MRTX Headlines

Recent News About These Companies

Mirati Therapeutics Stock Price History

May 26, 2025 | investing.com

New GTPase KRAS mutant inhibitors disclosed in Mirati patent

December 12, 2024 | bioworld.comB

Mirati Therapeutics Receives Untitled Letter from OPDP for Overstating Cancer Drug Efficacy

October 15, 2024 | policymed.comP

Pharma M&A rumour mill grinds out Mirati's name again

August 16, 2024 | pharmaphorum.comP

Mirati's Charles Baum takes the helm at Terremoto Biosciences

July 25, 2024 | fiercebiotech.comF

Mirati Therapeutics gets grant for combination therapy for treating kras G12C cancers

April 17, 2024 | pharmaceutical-technology.comP

Mirati Therapeutics gets grant for combination therapy for treating kras G12C cancers

April 17, 2024 | pharmaceutical-technology.comP

How this insider trader nailed every single stock trade

April 5, 2024 | finbold.comF

The workforce reduction at Mirati Therapeutics will take place over the next year and impacts more than 400 employees.

April 3, 2024 | sandiegouniontribune.comS

Mirati Therapeutics files patent for inhibitors of KRAS g12d

March 26, 2024 | pharmaceutical-technology.comP

Bristol Myers Squibb cuts hundreds of Mirati staffers months after closing $5.8B buyout

March 26, 2024 | fiercepharma.comF

Bristol Myers Squibb concludes acquisition of Mirati Therapeutics

January 26, 2024 | medicaldialogues.inM

Bristol Myers Squibb completes acquisition of Mirati Therapeutics

January 25, 2024 | pharmabiz.comP

Mirati Therapeutics Receives Marketing Authorization For KRAZATI From European Commission

January 10, 2024 | markets.businessinsider.com

European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

January 10, 2024 | finance.yahoo.com

Mirati Therapeutics Inc [MRTX] Stock sold by Insider Christensen Jamie for $0.14 million

January 2, 2024 | knoxdaily.comK

Evaluating Mirati Therapeutics' CVR Value In The Wake Of The Bristol Myers Acquisition

December 25, 2023 | seekingalpha.com

Bristol Myers to buy schizophrenia drugmaker Karuna Therapeutics for $14 bln

December 22, 2023 | reuters.com

Karuna Therapeutics soars after $14 billion takeover by Bristol Myers

December 22, 2023 | msn.com

Citigroup Downgrades Mirati Therapeutics (MRTX)

December 20, 2023 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BPMC, BBIO, GBT, EVTCY, and MRTX Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

$43.70 +0.88 (+2.04%)

Closing price 03:50 PM Eastern

Extended Trading

$43.12 -0.59 (-1.34%)

As of 04:20 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Blueprint Medicines NASDAQ:BPMC

$128.27 +0.07 (+0.05%)

Closing price 02:27 PM Eastern

Extended Trading

$128.27 0.00 (0.00%)

As of 04:20 PM Eastern

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Evotec OTCMKTS:EVTCY

$4.34 +0.12 (+2.84%)

As of 07/2/2025

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

Global Blood Therapeutics NASDAQ:GBT

Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD. In addition, the company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions; and GBT601, a hemoglobin polymerization inhibitor that is in Phase I development. It has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD and beta thalassemia; and Sanofi S.A. to two early-stage research programs in SCD. Global Blood Therapeutics, Inc. was incorporated in 2011 and is headquartered in South San Francisco, California.

Mirati Therapeutics NASDAQ:MRTX

Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time